ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services.
Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System.
Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 11.4K |
| Three Month Average Volume | 1.6M |
| High Low | |
| Fifty-Two Week High | 1.41 USD |
| Fifty-Two Week Low | 0.1251 USD |
| Fifty-Two Week High Date | 29 Sep 2023 |
| Fifty-Two Week Low Date | 06 Aug 2024 |
| Price and Volume | |
| Current Price | 0.22 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 48.75% |
| Thirteen Week Relative Price Change | -63.00% |
| Twenty-Six Week Relative Price Change | -76.03% |
| Fifty-Two Week Relative Price Change | -84.99% |
| Year-to-Date Relative Price Change | -69.09% |
| Price Change | |
| One Day Price Change | 15.79% |
| Thirteen Week Price Change | -60.40% |
| Twenty-Six Week Price Change | -73.65% |
| Five Day Price Change | 4.76% |
| Fifty-Two Week Price Change | -81.20% |
| Year-to-Date Price Change | -63.39% |
| Month-to-Date Price Change | 22.22% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.46077 USD |
| Book Value Per Share (Most Recent Quarter) | 0.1226 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.46077 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.1226 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.59282 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 3.98841 USD |
| Revenue Per Share (Trailing Twelve Months) | 3.14184 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -7.59043 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -4.9915 USD |
| Normalized (Last Fiscal Year) | -6.59302 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -7.59043 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -4.9915 USD |
| Including Extraordinary Items (Last Fiscal Year) | -7.59043 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -4.9915 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.55281 USD |
| Cash Per Share (Most Recent Quarter) | 0.14787 USD |
| Cash Flow Per Share (Last Fiscal Year) | -7.82016 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -4.74839 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.50161 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -72 |
| Cash Flow Revenue (Trailing Twelve Months) | -48 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -163.77% |
| Pretax Margin (Last Fiscal Year) | -200.31% |
| Pretax Margin (5 Year) | -133.66% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 20.44% |
| Gross Margin (Trailing Twelve Months) | 21.10% |
| Gross Margin (5 Year) | 29.01% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -94.61% |
| Operating Margin (Trailing Twelve Months) | -85.42% |
| Operating Margin (5 Year) | -69.55% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -200.31% |
| Net Profit Margin (Trailing Twelve Months) | -163.77% |
| Net Profit Margin (5 Year) | -133.66% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 6.42% |
| Revenue Growth (3 Year) | -0.47% |
| Revenue Change (Trailing Twelve Months) | -7.53% |
| Revenue Per Share Growth | -55.81% |
| Revenue Growth (5 Year) | -1.03% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 6.96% |
| Total Debt (5 Year) | 45.50% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 88.67% |
| EPS Change (Trailing Twelve Months) | 76.69% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | 4 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 3.0M |
| Net Debt (Last Fiscal Year) | 5.7M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 0 |
| Quick Ratio (Most Recent Quarter) | 0 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 0 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -5,454,000 |
| Free Cash Flow (Trailing Twelve Months) | -4,593,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -1 |
| Net Interest Coverage (Trailing Twelve Months) | -1 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | 431 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -123.58% |
| Return on Assets (Trailing Twelve Months) | -105.49% |
| Return on Assets (5 Year) | -78.08% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -1,367.44% |
| Return on Equity (Trailing Twelve Months) | -417.94% |
| Return on Equity (5 Year) | -375.60% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -369.62% |
| Return on Investment (Trailing Twelve Months) | -221.76% |
| Return on Investment (5 Year) | -133.94% |